XPRIZE Healthspan
The largest prize in XPRIZE history — $101 million for a therapy that measurably restores muscle, cognition, and immune function by at least ten years — the institutional, funded edge of the same frontier this thread charts.
- The competition's stated goal: teams must demonstrate a therapeutic treatment that restores muscle, cognitive, and immune function by a minimum of 10 years — with a stretch goal of 20 — in persons aged 50–80.
- The purse is $101 million, funded by Hevolution Foundation, Solve FSHD, and GSK among named donors, running from a 2023 launch to a final award in 2030.
- The foundation lists 198 competing teams — a live census of who, worldwide, believes functional age reversal is demonstrable this decade.
The prize's own competition page — rules, purse, timeline, team count, and donor roster, stated in the foundation's own terms.
XPRIZE founder and the recurring name across the mainstream-longevity ecosystem (Abundance360, Fountain Life, Singularity University) — several of which are queued for their own entries.
The named funders — a Saudi-backed longevity fund, a patient-advocacy foundation, and a pharmaceutical major, respectively; the coalition itself says something about where this field now sits.
EVERY NAME LINKS TO ITS PAGE ON THE MAP — SEE WHO ELSE CITES IT. NAMING A SOURCE IS NOT ENDORSING IT.
- How is 'restoring function by 10 years' actually measured — what are the muscle, cognition, and immune endpoints, and who validates them?
- What kinds of therapies dominate the 198 teams — drugs, gene therapies, protocols, devices — and does anything from the fringe end of this map appear among them?
- What happens to the therapies that demonstrate results — open publication, licensing, or enclosure?
This is the mainstream edge of the healing frontier: the same ambition the fringe devices on this thread claim — functional rejuvenation — here stated as a measurable target with institutional money, named judges, and a deadline. The Atlas charts both ends of that spectrum on one map deliberately.
The prize model itself is the interesting structure: rather than funding one lab, it defines a verifiable outcome and lets 198 teams race toward it in public — a governance pattern for frontier research that connects this entry to more than one thread of the map.
Will any team hit the 10-year restoration bar by 2030?
Milestone awards and finalist cuts are published as the competition progresses; the Atlas is tracking the finalist announcements as the field's most concrete public benchmark.
Report from the field →PureWave Cell
A locked array of neodymium magnets arranged on sacred-geometry principles, described as emitting a coherent low-frequency field — given free to beekeepers, sold to the public.
PhiRay
A $6,900 plasma-and-magnetic-field device marketed as the direct replacement for the maker's earlier Theraphi system — claimed to be 2–4x more powerful at roughly a quarter of the cost.
Piezo Phire
The most affordable device in the Implosion Group line (700 EUR) — a piezo-based localized 'implosive charge' unit launched at the maker's own FractalU conference.